The European Commission must now decide whether a new vaccine can be approved for use in the EU.
The vaccine has already received a positive assessment from the European Medicines Agency.
According to the Swedish media outlet Expressen, the agency reviews documentation on both effectiveness and safety before a vaccine can be recommended.
Only once the European Commission gives its approval can the vaccine be used in member states.
Also read: Not all apples are the same: These varieties contain the most health benefits
The decision is therefore the final step before the vaccine could potentially become part of future vaccination programs.
Primarily aimed at people over 50
The vaccine has been developed by the American pharmaceutical company Moderna. It is primarily intended for people over the age of 50.
According to Expressen, health authorities are working on solutions that could make vaccinations easier for citizens.
One of the goals is to examine whether fewer vaccinations can provide the same protection against disease.
Also read: These stars have openly talked about using weight-loss medication
Older age groups are often prioritized in vaccination programs because they may face a higher risk of severe illness.
Results from a study
The European Medicines Agency states that its assessment is based on a study involving around 8,000 participants.
According to the agency, the results show that the vaccine provides at least the same level of protection as separate vaccinations against the two diseases.
If the European Commission approves the vaccine, it will be able to protect against both COVID-19 and influenza with a single injection.
Also read: Five people died after infections linked to wet wipes
Sources: Nyheder 24, and Expressen.
Also read: Too much vitamin D sent man to hospital - here’s how the symptoms began